A phase I trial of single, ascending doses of DRL 17822 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2010
At a glance
- Drugs DRL 17822 (Primary)
- Indications Atherosclerosis; Chronic obstructive pulmonary disease; Dyslipidaemias; Lipid metabolism disorders
- Focus Adverse reactions
- Sponsors Dr Reddys Laboratories
- 29 Jun 2010 Results were reported at the 70th Annual Scientific Sessions of the American Diabetes Association.
- 25 Jun 2010 Status changed from recruiting to completed.
- 16 Jun 2009 New trial record.